TD Cowen analyst Tara Bancroft has maintained their neutral stance on WHWK stock, giving a Hold rating on July 29.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Tara Bancroft’s rating is based on Whitehawk Therapeutics’ strategic advancements in developing next-generation antibody-drug conjugates (ADCs). The company is on track to submit Investigational New Drug (IND) applications for three innovative ADCs over the next year, with two submissions expected by the end of the year and the third by mid-2026. The targets for these ADCs have been clinically validated, and the use of HANGZHOU’s CPT113 linker platform is anticipated to enhance their effectiveness.
Despite these promising developments, the Hold rating reflects the inherent risks and uncertainties associated with drug development. While the management is optimistic about overcoming previous toxicity challenges and improving response rates, the clinical outcomes remain to be seen. The Hold rating suggests a cautious approach, acknowledging the potential for success while considering the time and challenges involved in bringing these therapies to market.
In another report released on July 29, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $2.00 price target.